Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptidylprolyl isomerase A pseudogene 23 (PPIAP23) is classified as a pseudogene, meaning it is a nonfunctional DNA segment that resembles the functional gene encoding peptidylprolyl isomerase A (PPIA)[1][5][6]. Pseudogenes usually arise by duplication or retrotransposition events, often acquiring disabling mutations such as frameshifts or premature stop codons that prevent protein expression[2][6]. PPIAP23 itself does not encode a functional protein and is not considered a direct therapeutic target, receptor, enzyme, or otherwise druggable entity[1][5][6]. Pseudogenes may sometimes regulate gene expression at the RNA level, but there is no evidence for a specific biological, biomarker, or disease role for PPIAP23 at this time[1][2][5][6]. Its primary function is as a genomic sequence homologous to the protein-coding PPIA gene (cyclophilin A), which is distinct and pharmacologically relevant, but PPIAP23 itself has no independent therapeutic or clinical significance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptidylprolyl isomerase A pseudogene 23 (PPIAP23).